The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
42
Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
blood draw
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
RECRUITINGassess the change in Ki67
The change in Ki67 expression on immunohistochemical staining from baseline to at least 2 weeks of ET will be assessed.
Time frame: baseline to at least 2 weeks of endocrine therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.